Recombinant Human Anti-ZIKV ED3 Antibody (ZKA190) (CAT#: PABC-496)

Figure 1 ZKA190 was tested for neutralization of four strains of ZIKV, as determined by the percentage of infected Vero cells in the presence of increasing amounts of mAbs.

Data are representative of at least two independent experiments.

Wang, J., Bardelli, M., Espinosa, D. A., Pedotti, M., Ng, T. S., Bianchi, S., ... & Jaconi, S. (2017). A human bi-specific antibody against Zika virus with high therapeutic potential. Cell, 171(1), 229-241.

Figure 2 Therapeutic Efficacy of ZKA190.

ZKA190 or ZKA190-LALA were administered at 15 mg/kg at different time-points after ZIKV infection to A129 mice challenged with a lethal dose of ZIKV strain MP1745. (A) A Kaplan-Meier survival curve is shown. Experiments used N = 5 mice per group. Significance was determined by using the Mantel-Cox log-rank test. ZKA190 and ZKA190-LALA administered on day 1, 2, 3 or 4 versus Ctr., p = 0.0016. (B) Morbidity score of mice monitored over a 14-day period. (C) Mice were monitored over a 14-day period for body weight loss. Control mAb is MPE8 specific for RSV F protein.

Wang, J., Bardelli, M., Espinosa, D. A., Pedotti, M., Ng, T. S., Bianchi, S., ... & Jaconi, S. (2017). A human bi-specific antibody against Zika virus with high therapeutic potential. Cell, 171(1), 229-241.